Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | GFER | P55789 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342194 | 0.79 | KDM4E (0.64) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL3343038 | 0.79 | GFER (0.64) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL3343853 | 0.79 | GFER (0.64) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL638777 | 0.79 | GFER (0.58) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL3342202 | 0.79 | GFER (0.58) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL638781 | 0.79 | GFER (0.53) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL3343847 | 0.79 | ALDH1A1 (0.58) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL3347321 | 0.79 | KDM4E (0.58) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL258911 | 0.78 | GAA (1.00) | GAAKDM4EGFERHDAC8ALDH1A1 | |
| SCHEMBL639362 | 0.77 | GFER (0.61) | GAAKDM4EGFERHDAC8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE | 2010-06-24 | — | — | US | claimed |
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE | 2010-06-24 | — | — | US | disclosed |
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE | 2010-06-24 | — | — | US | disclosed |
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160401-A1 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH | TYR, TH, PAH | GAA 58/4885KDM4E 1018/4885GFER 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.